Alligator: New OPTIMZE-1 Readout and Financing - Redeye
Redeye provides its view on the recent financing of SEK80m and the 18-month OPTIMIZE-1 readout, a phase II study of mitazalimab combined with FOLFIRINOX in late-stage pancreatic cancer.
ANNONS
Redeye provides its view on the recent financing of SEK80m and the 18-month OPTIMIZE-1 readout, a phase II study of mitazalimab combined with FOLFIRINOX in late-stage pancreatic cancer.